Donanemab

← Pipeline

Donanemab

Eli Lilly · Alzheimer's disease
Approved / Late-stage active active, not recruiting CT.gov grounded

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Phase
Approved / Late-stage
Status
active
Recruitment
active, not recruiting
Confidence
high
Watch priority
1
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Eli Lilly
Trial IDs
NCT04437511
ClinicalTrials.gov exact matches: NCT04437511

Regions and recruitment

Active in 9 regions
United States Australia Canada Czechia Japan Netherlands Poland Puerto Rico United Kingdom

Indication tags

Alzheimer's early symptomatic Alzheimer's

Milestones and catalysts

Last milestone
Late-stage and regulatory momentum has made this one of the central Alzheimer's programs to track.
Next expected catalyst
Further rollout, label evolution, and follow-up data.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and same mechanism with Donanemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and same mechanism with Donanemab.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026
Priority 2
Mid-stage active active, not recruiting

A serious tau program that matters because the Alzheimer's field still needs credible combination therapy attempts.

Shown because it shares same disease bench and same modality with Donanemab.
Mechanism
anti-MTBR tau antibody
Modality
monoclonal antibody
Next catalyst
Whether the tau-plus-amyloid combination thesis produces a clearer signal than monotherapy tracks.
Last verified
20 Apr 2026
Priority 2
Late-stage active active, not recruiting

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Shown because it shares same disease bench and shared biology: alzheimer's with Donanemab.
Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Next catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT04437511 ClinicalTrials.gov search Lilly pipeline
Scroll to Top